Saitama Medical University International Medical Center Delivers Radiosurgery to Moving Lung Tumors

SUNNYVALE, Calif., June 3 /PRNewswire-AsiaNet/ --

             Saitama Medical University International Medical Center
                Delivers Radiosurgery to Moving Lung Tumors

   Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
radiosurgery, announced today that Saitama Medical University International
Medical Center in Japan has become the first hospital in Japan to deliver a
CyberKnife radiosurgery treatment using the Synchrony Respiratory Tracking
System. Their first treatment using the Synchrony System was delivered over a
three day period from April 26-28, 2010 to a female patient with metastatic
lung cancer. Saitama Medical University International Medical Center is one of
the leading facilities for new advances in medical care in Japan.

   The Synchrony System, which is a component of the CyberKnife
Robotic Radiosurgery System, monitors and tracks a patient's respiratory
motion in real time throughout the CyberKnife treatment, allowing doctors to
treat to treat complex moving tumors with sub-millimeter targeting accuracy.
The Synchrony System tracks tumor motion, which is especially important for
tumors that move with respiration in areas of the body such as the lung, and
dynamically directs the delivery of highly accurate radiation beams to the
moving tumor. The Synchrony System constantly updates its correlation model,
automatically correcting for any changes in respiration or tumor movement.
This allows the patient to breathe comfortably during treatment and allows
the clinician to reduce radiation exposure to surrounding healthy tissues and
critical structures.

   The Japanese Ministry of Health, Labor and Welfare (MHLW) granted
Shonin approval of the CyberKnife System for use in the treatment of
extracranial tumors, including tumors that move with respiration in June,
2008, This regulatory approval dramatically expanded the types of patients
that can be treated with radiosurgery to include those with cancers of the
spine, lung, liver, pancreas and prostate. In April 2010 fiducial markers
that are compatible with the CyberKnife System were approved for use,
enabling this recent lung treatment with the Synchrony System.

   Presently there are 21 CyberKnife Systems installed throughout
Japan. Worldwide use of the CyberKnife System to treat lung cancer grew 25
percent year over year in calendar year 2009 and presently more than 12,000
lung cancer patients have been treated.